Nursing Elites

1. A client with peptic ulcer disease is prescribed omeprazole. Which finding should indicate to the nurse that the medication is effective?

• A. Relief of headache
• B. Relief of nausea
• C. Relief of abdominal pain
• D. Relief of heartburn

Correct answer: C

Rationale: Relief of abdominal pain is a key indicator of omeprazole effectively treating peptic ulcer disease. Omeprazole works by reducing stomach acid production, which helps alleviate abdominal pain associated with peptic ulcers. While relief of other symptoms like headache, nausea, and heartburn may also occur, the primary therapeutic goal of omeprazole in peptic ulcer disease is to reduce abdominal pain caused by gastric irritation. Therefore, the relief of abdominal pain is the most significant finding to indicate the effectiveness of omeprazole in this context. Choices A, B, and D may improve as a result of decreased stomach acid production, but they are not as specific or central to the therapeutic goal of treating peptic ulcer disease as the relief of abdominal pain.

2. A client has been prescribed Valsartan. Which of the following adverse effects should the nurse monitor?

• A. Hyperkalemia
• B. Hypoglycemia
• C. Bradycardia
• D. Hypercalcemia

Correct answer: A

Rationale: Corrected Rationale: Valsartan is an angiotensin II receptor blocker (ARB) that can lead to hyperkalemia by inhibiting the action of aldosterone. Hyperkalemia is a potential adverse effect, making it essential for the nurse to closely monitor the client's potassium levels to prevent complications such as cardiac arrhythmias. Incorrect Options Rationale: - Option B, Hypoglycemia, is not a common adverse effect of Valsartan. - Option C, Bradycardia, is not typically associated with Valsartan use. - Option D, Hypercalcemia, is not a known adverse effect of Valsartan; instead, Valsartan can lead to hyperkalemia.

3. When starting Alfuzosin for the treatment of Benign Prostatic Hyperplasia, a nurse is providing teaching to a client. The nurse should instruct the client that which of the following is an adverse effect of this medication?

• A. Bradycardia
• B. Edema
• C. Hypotension
• D. Tremor

Correct answer: C

Rationale: The correct adverse effect of Alfuzosin is hypotension. Alfuzosin relaxes muscle tone in veins, leading to decreased cardiac output and subsequent hypotension. Patients on this medication should be advised to change positions slowly to prevent a sudden drop in blood pressure. Choice A, Bradycardia, is not a common adverse effect of Alfuzosin. Choice B, Edema, is not typically associated with Alfuzosin use. Choice D, Tremor, is also not a common adverse effect of Alfuzosin.

4. A client has a new diagnosis of Fibromyalgia. Which of the following medications should the nurse anticipate being prescribed for this client?

• A. Colchicine
• B. Hydroxychloroquine
• C. Auranofin
• D. Duloxetine

Correct answer: D

Rationale: The correct answer is D, Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor commonly used to manage fibromyalgia. It helps in reducing pain and improving mood in individuals with this condition. Colchicine (Choice A) is primarily used to treat gout, while Hydroxychloroquine (Choice B) and Auranofin (Choice C) are medications used to manage conditions like rheumatoid arthritis and lupus, not fibromyalgia.

5. While assessing a client taking Amiodarone to treat Atrial Fibrillation, which of the following findings is indicative of Amiodarone toxicity?

• A. Light yellow urine
• B. Report of tinnitus
• C. Productive cough
• D. Blue-gray skin discoloration

Correct answer: C

Rationale: Productive cough can indicate pulmonary toxicity, which is a known adverse effect of Amiodarone. Clients on Amiodarone should be monitored for signs of pulmonary toxicity such as cough, dyspnea, and chest pain. This is important to detect early and prevent serious complications. The other options are not typically associated with Amiodarone toxicity. Light yellow urine is not a common sign, tinnitus is more related to ear problems, and blue-gray skin discoloration is not a recognized symptom of Amiodarone toxicity.

Similar Questions